We are live on ! Find out more
SMMT icon

Summit Therapeutics

54 hedge funds and large institutions have $23.3M invested in Summit Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

395% more call options, than puts

Call options by funds: $638K | Put options by funds: $129K

123% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 13

0.05% less ownership

Funds ownership: 11.37%11.32% (-0.05%)

7% less funds holding

Funds holding: 5854 (-4)

23% less capital invested

Capital invested by funds: $30.4M → $23.3M (-$7.12M)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
54
Holders Change
-4
Holders Change %
-6.9%
% of All Funds
0.95%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
29
Reduced
13
Closed
8
Calls
$638K
Puts
$129K
Net Calls
+$509K
Net Calls Change
-$304K

SMMT Hedge Fund Activity: Q3 2021 in Review

54 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2021, worth a combined $23.3M — down 23% from $30.4M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SMMT and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 29 added.

The largest buyer was Northern Trust, adding an estimated $1.15M. The largest seller was Polar Capital Holdings, cutting an estimated $4.01M.

  • 54 institutional investors held Summit Therapeutics (SMMT) as of Q3 2021, down from 58 in Q2 2021.
  • Funds reported $23.3M of Summit Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
  • 4 funds opened new Summit Therapeutics positions in Q3 2021 and 8 closed out, a net change of -4 holders.
  • The largest Summit Therapeutics buyer in Q3 2021 was Northern Trust, an estimated $1.15M added.
  • The largest Summit Therapeutics seller in Q3 2021 was Polar Capital Holdings, an estimated $4.01M sold.

Based on aggregated 13F filings for Q3 2021.